Trial reportRheumatology international2007
A pravastatin dose-escalation study in systemic lupus erythematosus.
Trial report in Rheumatology international, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Statin therapy in systemic lupus erythematosus: a meta-analysis of disease activity and inflammatory biomarkers.Lupus science & medicine · 2026Pooled it
- Quantitative determination of pravastatin and its metabolite 3α-hydroxy pravastatin in plasma and urine of pregnant patients by LC-MS/MS.Biomedical chromatography : BMC · 2016Trial
- Atorvastatin effect on systemic lupus erythematosus disease activity: a double-blind randomized clinical trial.Clinical rheumatology · 2014 · on this mapTrial
- Use of atorvastatin in systemic lupus erythematosus in children and adolescents.Arthritis and rheumatism · 2012Trial
- Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics.Signal transduction and targeted therapy · 2025Review
- CD38 in SLE CD4 T cells promotes CaNature communications · 2024Article
- Renin-Angiotensin System-Modifying Antihypertensive Drugs Can Reduce the Risk of Cardiovascular Complications in Lupus: A Retrospective Cohort Study.The American journal of medicine · 2023Article
- Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis.International journal of women's dermatology · 2021Review
- Management of cardiovascular disease in patients with systemic lupus erythematosus.Expert opinion on pharmacotherapy · 2020Review
- Lipid Testing and Statin Prescriptions Among Medicaid Recipients With Systemic Lupus Erythematosus or Diabetes Mellitus and the General Medicaid Population.Arthritis care & research · 2019Article
- Immune modulatory effects of statins.Immunology · 2018Review
- Dyslipidemia in systemic lupus erythematosus.Immunologic research · 2017Review
- Pathogenesis and treatment of atherosclerosis in lupus.Rheumatic diseases clinics of North America · 2014Review
- Statins and autoimmunity.Immunologic research · 2013Review
- Treatment of dyslipidemia in idiopathic inflammatory myositis: results of the International Myositis Assessment and Clinical Studies Group survey.Clinical rheumatology · 2012Article
- Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials.Current pharmaceutical design · 2012Review
- Statin therapy in lupus-mediated atherogenesis: two birds with one stone?Annals of the rheumatic diseases · 2011Review
- The role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (statins) in modern rheumatology.Therapeutic advances in musculoskeletal disease · 2010Article
- Management of cardiovascular complications in systemic lupus erythematosus.International journal of clinical rheumatology · 2010Article
- Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis.Arthritis research & therapy · 2010Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Statin medications have been suggested for widespread use in patients with systemic lupus erythematosus (SLE). We studied the dose effectiveness and tolerability of pravastatin in SLE. We compared 41 SLE subjects in a two-month open-label dose-titration study of pravastatin to 22 SLE controls. Lipids, ALT, CPK, CRP, adverse effects were assessed. Linear mixed models assessed changes in lipids and CRP, comparing pravastatin subjects to controls. After 1 month of pravastatin 10 mg a day, total cholesterol decreased by 16% (+/-12.1%) and LDL by 24% (+/-17%), compared with 1.8% (+/-7.5%) and 2.6% (+/-8.6%) decreases in controls (P < 0.001). CRP did not decline. Glucocorticoids appeared to decrease pravastatin effectiveness. Serum CPK increased in one subject. Pravastatin reduced LDL and total cholesterol levels approximately the same degree observed in normal individuals, but the effect appeared blunted in those on modest doses of glucocorticoids and those with higher BMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.